Xin Zhi Ma

This inventor holds 15 USPTO granted patents and 15 published patent applications and 4 EPO patents. Top assignees: Dell Products Inc., Glaxosmithkline Intellectual Property Development Limited, Huawei Technologies Co., Limited. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xin Zhi Ma. Retrieved from https://idiyas.com/inventor/xin-zhi-ma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 15)

% Patents Active = 80.0

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 2.4

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Shenzhen, CN (2013)
Ningbo, CN (2023)
Shanghai, CN (2014 - 2024)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

2 out of 27,557

Huawei Technologies Co., Limited

Shanghai Institute of Endocrine and Metabolic Diseases

patent

6. 1 out of 1

Sph Sine Pharmaceutical Laboratories Co., Ltd

patent

7. 1 out of 834,513

Other

patents

Years Active: 2013-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12764903 - Liquid-assisted and thermoelectric-based temperature control for servers and other electronic equipment (2026-10-13),

2. 12596415 - Managing thermal capabilities of an information handling system in a chamber-less environment (2026-04-07),

3. 12513866 - Air-assisted immersion cooling systems (2025-12-30),

4. 12268515 - Multi-dimensional broad-spectrum clinical in-situ testing equipment for evaluating mechanical properties of plantar soft tissue (2025-04-08),

5. 12225682 - Temperature adaptive information handling system (2025-02-11),

6. 12105568 - Airflow guide with integrated power conduction (2024-10-01),

7. 12036251 - Strain for preventing and treating metabolic diseases and use thereof (2024-07-16),

8. D984187 - Hammock stand (2023-04-25),

9. 11589476 - Hybrid oil immersion server and associated computing rack (2023-02-21),

10. 11096281 - Power delivery system (2021-08-17),

11. 9902735 - Heteroaryl substituted compounds as RORγ inhibitors (2018-02-27),

12. 9902715 - Compounds (2018-02-27),

13. 9868724 - Compounds (2018-01-16),

14. 8718212 - Rate matching method and apparatus (2014-05-06),

15. 8468017 - Multi-stage quantization method and device (2013-06-18),

Title: Innovator Xin Ma: Pioneering Advances in Metabolic Disease Treatment

Introduction: Xin Ma, based in Shanghai, China, is an accomplished inventor known for his contributions to the field of metabolic disease treatment. With a unique strain designated as SSYD-3, Xin’s innovation showcases remarkable advancements over existing treatments, focusing on both efficacy and safety.

Latest Patents: Xin Ma holds a notable patent for a strain aimed at preventing and treating metabolic diseases. The patent details a specific strain named SSYD-3, which is documented under accession number CGMCC No. 14764. This strain boasts superior fermentation performance, storage stability, acid and bile resistance compared to the previously established ATCC BAA835 strain. The significant enhancements offered by SSYD-3 present a promising avenue for effectively managing metabolic disorders.

Career Highlights: Throughout his career, Xin has made substantial contributions while working for reputable organizations, including Sph Sine Pharmaceutical Laboratories Co., Ltd and Shanghai Institute of Endocrine and Metabolic Diseases. His professional journey reflects a dedication to research and innovation in metabolic health.

Collaborations: Xin Ma has collaborated with notable peers such as Bin Wen and Guang Ning. These partnerships have enriched his research endeavors, fostering an environment of shared knowledge and innovation in the fight against metabolic diseases.

Conclusion: Xin Ma’s innovative work in developing the SSYD-3 strain marks a significant milestone in the treatment of metabolic diseases. His dedication to research and collaboration within the scientific community promises to pave the way for further advancements in this critical area of health.

Profile summary based on public USPTO records.